| Revenue growth | -2% CAGR over FY23-26. |
|---|---|
| Margins | Transition costs in FY27; long-term margin uplift via procurement optimization. |
| Demand visibility | Strong legacy brand loyalty; 'Minipress' has ~63% value share. |
| Management confidence | High: focus on re-establishing in-house promotion to unlock value. |
Growth
FY26 revenue at ₹354 Cr (-2% CAGR FY23-26). PAT at ₹93 Cr (-3% CAGR).
Outlook
Targets above-market growth via a dedicated 900+ field force and aggressive M&A strategy for chronic therapies.
Risks
One-time transition costs and partnership termination fees expected in Q2-Q4 FY27 to impact margins.
Investor Presentation filed with BSE, NSE: NOVARTIND. Summary written with AI assistance from the document.
Novartis India Ltd: key numbers
- Share price
- ₹1,961.40
- Market cap
- ₹4,843 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- 49.5×Sector 50.4×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 0.15%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novartis India Ltd
All →Novartis India Annual General Meeting
Novartis India issued a corrigendum to its 78th AGM notice. This correction clarifies ESOP 2026 scheme details and the company's nature of industry.
Novartis India Earnings Call Transcript: Key Takeaways
Novartis India transition to ChrysCapital ownership (70.68%), pivoting from a partner-led model to a direct, in-house commercial platform focusing on chronic therapies like cardiology and ophthalmology.
Novartis India Other Announcement
Novartis India dispatched physical letters with the FY25-26 Annual Report web-link to non-email shareholders per Reg 36(1)(b). This is a routine compliance communication with no financial or business impact.
Novartis India Partnership
Novartis India signed an exclusive distribution deal with Novartis Healthcare for its retina portfolio in India. Upfront consideration of INR 10 Crore expands NIL's ophthalmology presence.
- Value
- ₹10.00 Cr
Novartis India Business Update
Novartis India acquired trademarks 'Minipress' and 'Minipres' from Pfizer for ₹1,250.001 Crore. The IP acquisition strengthens its hypertension and BPH portfolio in India.
- Value
- ₹1,250 Cr
Novartis India Acquisition Worth ₹1,250 Cr
Novartis India acquired Minipress/Minipres trademarks and related IP from Pfizer for ₹1,250 Crore. The board approved and the asset purchase agreement was executed on September 7, 2026.
- Value
- ₹1,250 Cr